Azole Resistance in Candida glabrata

Sarah G. Whaley, Phillip Rogers

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Candida infections have increased due to the growth and expansion of susceptible patient populations. The azole fluconazole is the most widely prescribed antifungal, but rising rates of clinical resistance among Candida glabrata isolates have greatly limited its utility. A better understanding of the mechanisms of azole antifungal resistance will provide information needed to overcome this clinical problem and reclaim this antifungal class as an option for empiric treatment of Candida infections. By far, the most frequent mechanism of azole resistance in C. glabrata is the overexpression of multidrug transporters due to activating mutations in the gene encoding transcription factor Pdr1. In this review, we will discuss the molecular and genetic basis of azole resistance in C. glabrata with particular attention given to the most recent discoveries in this field.

Original languageEnglish (US)
Article number41
JournalCurrent Infectious Disease Reports
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Candida glabrata
Azoles
Candida
Fluconazole
Infection
Molecular Biology
Transcription Factors
Mutation
Growth
Population
Genes

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

Azole Resistance in Candida glabrata. / Whaley, Sarah G.; Rogers, Phillip.

In: Current Infectious Disease Reports, Vol. 18, No. 12, 41, 01.12.2016.

Research output: Contribution to journalReview article

@article{379f90d328c84b08a2858d67ab853191,
title = "Azole Resistance in Candida glabrata",
abstract = "Candida infections have increased due to the growth and expansion of susceptible patient populations. The azole fluconazole is the most widely prescribed antifungal, but rising rates of clinical resistance among Candida glabrata isolates have greatly limited its utility. A better understanding of the mechanisms of azole antifungal resistance will provide information needed to overcome this clinical problem and reclaim this antifungal class as an option for empiric treatment of Candida infections. By far, the most frequent mechanism of azole resistance in C. glabrata is the overexpression of multidrug transporters due to activating mutations in the gene encoding transcription factor Pdr1. In this review, we will discuss the molecular and genetic basis of azole resistance in C. glabrata with particular attention given to the most recent discoveries in this field.",
author = "Whaley, {Sarah G.} and Phillip Rogers",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s11908-016-0554-5",
language = "English (US)",
volume = "18",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "12",

}

TY - JOUR

T1 - Azole Resistance in Candida glabrata

AU - Whaley, Sarah G.

AU - Rogers, Phillip

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Candida infections have increased due to the growth and expansion of susceptible patient populations. The azole fluconazole is the most widely prescribed antifungal, but rising rates of clinical resistance among Candida glabrata isolates have greatly limited its utility. A better understanding of the mechanisms of azole antifungal resistance will provide information needed to overcome this clinical problem and reclaim this antifungal class as an option for empiric treatment of Candida infections. By far, the most frequent mechanism of azole resistance in C. glabrata is the overexpression of multidrug transporters due to activating mutations in the gene encoding transcription factor Pdr1. In this review, we will discuss the molecular and genetic basis of azole resistance in C. glabrata with particular attention given to the most recent discoveries in this field.

AB - Candida infections have increased due to the growth and expansion of susceptible patient populations. The azole fluconazole is the most widely prescribed antifungal, but rising rates of clinical resistance among Candida glabrata isolates have greatly limited its utility. A better understanding of the mechanisms of azole antifungal resistance will provide information needed to overcome this clinical problem and reclaim this antifungal class as an option for empiric treatment of Candida infections. By far, the most frequent mechanism of azole resistance in C. glabrata is the overexpression of multidrug transporters due to activating mutations in the gene encoding transcription factor Pdr1. In this review, we will discuss the molecular and genetic basis of azole resistance in C. glabrata with particular attention given to the most recent discoveries in this field.

UR - http://www.scopus.com/inward/record.url?scp=84992092042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992092042&partnerID=8YFLogxK

U2 - 10.1007/s11908-016-0554-5

DO - 10.1007/s11908-016-0554-5

M3 - Review article

VL - 18

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 12

M1 - 41

ER -